Mirum Pharmaceuticals, Inc. - common stock (NQ:MIRM)

79.88 -1.56 (-1.91%)

Delayed Quote Updated: 10:57 AM EDT, Oct 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Mirum Pharmaceuticals, Inc. - common stock

< Previous 1 2 3 4 5 6 7 8 9

...

13 14 Next >

Analyst Ratings For Mirum Pharmaceuticals ↗

April 17, 2024

Via Benzinga

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 10, 2024

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals’ LIVMARLI (maralixibat oral solution) Receives Positive Reimbursement Recommendation by Canada’s CADTH for Patients with Cholestatic Pruritus in Alagille Syndrome

April 02, 2024

From Mirum Pharmaceuticals, Inc.

Via Business Wire

$5M Bet On Snowflake? Check Out These 4 Stocks Insiders Are Buying ↗

March 28, 2024

Although U.S. stocks closed higher on Wednesday, there were a few notable insider trades.

Via Benzinga

Cracking The Code: Understanding Analyst Reviews For Mirum Pharmaceuticals ↗

March 18, 2024

Via Benzinga

Critical Insights From Mirum Pharmaceuticals Analyst Ratings: What You Need To Know ↗

February 29, 2024

Via Benzinga

Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors

March 25, 2024

From Sagimet Biosciences Inc.

Via GlobeNewswire

FDA Approves Mirum's Livmarli For Liver Disease In Kids As Young As 5 Years: Analyst Bullish On Label Expansion Strategy ↗

March 14, 2024

FDA approves Livmarli by Mirum Pharmaceuticals for cholestatic pruritus in PFIC patients ≥5 years old. Data from Phase 3 MARCH study. Analysts bullish on broader coverage in 2024, with price target...

Via Benzinga

Mirum Pharmaceuticals’ LIVMARLI Receives FDA Approval for Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis

March 13, 2024

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals: Q4 Earnings Insights ↗

February 28, 2024

Via Benzinga

Preview: Mirum Pharmaceuticals's Earnings ↗

February 27, 2024

Via Benzinga

Where Mirum Pharmaceuticals Stands With Analysts ↗

January 11, 2024

Via Benzinga

The Latest Analyst Ratings For Mirum Pharmaceuticals ↗

December 19, 2023

Via Benzinga

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 08, 2024

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences

March 05, 2024

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Hepatology Publishes Six-Year Data Demonstrating Improved Clinical Outcomes in Patients with Alagille Syndrome Treated with Mirum’s LIVMARLI

February 29, 2024

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Business Update

February 28, 2024

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2023 Financial Results and Host Conference Call on February 28, 2024

February 21, 2024

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 09, 2024

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 19, 2024

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals Appoints Joanne Quan, MD as Chief Medical Officer

January 16, 2024

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 10, 2024

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Veradigm, Aehr Test Systems, Saratoga Investment And Other Big Stocks Moving Lower On Wednesday ↗

January 10, 2024

U.S. stocks traded slightly higher, with the Dow Jones index gaining over 20 points on Wednesday. Shares of Veradigm Inc. (NASDAQ: MDRX) shares fell sharply during Wednesday’s session.

Via Benzinga

Topics Stocks

Mirum Pharmaceuticals Announces Preliminary Unaudited 2023 Net Revenue and Provides Corporate Updates

January 08, 2024

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

January 03, 2024

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Uber To Rally Over 13%? Here Are 10 Top Analyst Forecasts For Tuesday ↗

December 19, 2023

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Via Benzinga

Mirum Pharmaceuticals Announces Data from EMBARK Phase 2b Study for Biliary Atresia

December 18, 2023

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Why Lantheus Holdings Shares Are Trading Lower By Over 22%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

December 18, 2023

Shares of Lantheus Holdings, Inc. (NASDAQ: LNTH) fell sharply during Monday’s session after the company and POINT Biopharma announced topline results from the pivotal phase 3 SPLASH study in metastatic...

Via Benzinga

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 08, 2023

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Stonegate Healthcare Partners Releases Report on Transformative Therapies for Pruritus Management

November 30, 2023

Dallas, Texas--(Newsfile Corp. - November 30, 2023) - Stonegate Healthcare Partners is pleased to...

Via Newsfile

< Previous 1 2 3 4 5 6 7 8 9

...

13 14 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.